Dianthus Therapeutics Inc. (DNTH) Next Earnings Date & Options-Implied ±7.2% Move

$82.70 +0.47% NASDAQ • Public Delayed / 60s Snapshot

Dianthus Therapeutics Inc. (DNTH) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (58/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (-26.0% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.

ROARABLE D+ • SELL / AVOID Cap $4.63B
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510058
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw D+ · Rk D
Cash (9)Whales (10)SEC (8)Macro (14)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE+0% Base Target
$124 Bull$83 Base$65 Bear
🔴 SUNDAY NIGHT PREP • 7:00 PM ET
WHALE OPTIONS TUG-OF-WAR:58% Call Buyers ($2.6M)
42% PutsMax Pain: $81.00
NEXT EST. REPORT: Dec 30, 2026 (~58 DAYS)

Options-Implied Post-Earnings ±7.2% Bell Curve

±$5.95 Expected Swing
$76.75 (-7.2%)Spot $82.70$88.65 (+7.2%)
TRADER CROWD SENTIMENT POLL

Will DNTH Beat & Rip or Miss Next Quarter?

Trailing EPS: $-2.90 • YoY Revenue Growth: -65%

48% Bullish Beat52% Bearish Miss

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$2.0M-$162.3M-$129.2M44%
FY 20242024-12-31$6.2M-$85.0M-$78.5M44%
FY 20232023-12-31$2.8M-$43.5M-$37.0M44%
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Forensic Quant Desk

Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring DNTH)

  • ✓Live walkthrough of DNTH's RQD Radar, SEC cash-conversion gap & downside levels
  • ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
  • ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
DNTH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -6.17%📐 HORIZONTAL RANGE
2026-10-30O $81.29H $83.73L $80.58C $82.38VOL 496.9K
RES: $139.2SUP: $66.06SMA50: $92.76SMA200: $85.03
$122.9$102.2$81.55$60.89$40.23RES $139.2SUP $66.06$82.382026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DNTH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
13.5%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DNTH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DNTH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DNTH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DNTH Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is DNTH's next earnings date?

Based on SEC filing cadence, Dianthus Therapeutics Inc. (DNTH)'s next quarterly earnings window is estimated around Dec 30, 2026.

How much is DNTH stock expected to move on earnings?

Options markets currently imply a ±7.2% post-earnings move for DNTH, projecting a trading range between $76.75 and $88.65.